The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer

The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer

The definitive characterization of common cancer stem cell (CSCs) subpopulations in breast cancer subtypes with distinct genotypic and phenotypic features remains an ongoing challenge. In this study, we have used a non-biased genome wide screening approach to identify transcriptional networks that m...

Detaylı Bibliyografya
Asıl Yazarlar:	Walsh, CA, Akrap, N, Garre, E, Magnusson, Y, Harrison, H, Andersson, D, Jonasson, E, Rafnsdottir, S, Choudhry, H, Buffa, F, Ragoussis, J, Ståhlberg, A, Harris, A, Landberg, G
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Public Library of Science 2020

Benzer Materyaller

The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer.
Yazar:: Claire A Walsh, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway
Yazar:: Yasuhiro Kato, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Identification of Distinct Breast Cancer Stem Cell Populations Based on Single-Cell Analyses of Functionally Enriched Stem and Progenitor Pools
Yazar:: Nina Akrap, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

Proteomics of cell‐free breast cancer scaffolds identify clinically relevant imprinted proteins and cancer‐progressing properties
Yazar:: Anna Gustafsson, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion
Yazar:: Sara Rhost, ve diğerleri
Baskı/Yayın Bilgisi: (2018-11-01)

Expression of HMGCS2 and its correlation with clinopathological characteristics in bladder cancer
Yazar:: ZHU Shuai, ve diğerleri
Baskı/Yayın Bilgisi: (2021-12-01)

Inhibition of Lung Squamous Cancer Target HMGCS1 Promotes Cellular Ferroptosis
Yazar:: Yinyun NI, ve diğerleri
Baskı/Yayın Bilgisi: (2024-05-01)

Hmgcs2 is the hub gene in diabetic cardiomyopathy and is negatively regulated by Hmgcs2, promoting high glucose‐induced cardiomyocyte injury
Yazar:: Ying Wang, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Differentially expressed miRNAs in Luminal and Basal-like breast cancer
Yazar:: Ming-Juan ZHAO, ve diğerleri
Baskı/Yayın Bilgisi: (2021-06-01)

Mevalonate Metabolism in Cancer Stemness and Trained Immunity
Yazar:: Georg Gruenbacher, ve diğerleri
Baskı/Yayın Bilgisi: (2018-09-01)

Mevalonate metabolism governs cancer immune surveillance
Yazar:: Georg Gruenbacher, ve diğerleri
Baskı/Yayın Bilgisi: (2017-10-01)

The Effect of Hypoxic and Normoxic Culturing Conditions in Different Breast Cancer 3D Model Systems
Yazar:: Andreas Svanström, ve diğerleri
Baskı/Yayın Bilgisi: (2021-11-01)

Debottlenecking mevalonate pathway for antimalarial drug precursor amorphadiene biosynthesis in Yarrowia lipolytica
Yazar:: Monireh Marsafari, ve diğerleri
Baskı/Yayın Bilgisi: (2020-06-01)

HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells
Yazar:: Fat-Moon Suk, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

The Mevalonate Pathway, a Metabolic Target in Cancer Therapy
Yazar:: Borja Guerra, ve diğerleri
Baskı/Yayın Bilgisi: (2021-02-01)

Pathology-based deep learning features for predicting basal and luminal subtypes in bladder cancer
Yazar:: Zongtai Zheng, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

Patient-derived scaffolds representing breast cancer microenvironments influence chemotherapy responses in adapted cancer cells consistent with clinical features
Yazar:: Maria Carmen Leiva, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer
Yazar:: Karoline Berger, ve diğerleri
Baskı/Yayın Bilgisi: (2021-02-01)

Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
Yazar:: Andy Göbel, ve diğerleri
Baskı/Yayın Bilgisi: (2020-07-01)

Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy
Yazar:: Linyuan Xue, ve diğerleri
Baskı/Yayın Bilgisi: (2020-08-01)

Potential Role of HMGCS2 in Tumor Angiogenesis in Colorectal Cancer and Its Potential Use as a Diagnostic Marker
Yazar:: Kejian Zou, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome
Yazar:: Hoffmann Georg F, ve diğerleri
Baskı/Yayın Bilgisi: (2006-04-01)

Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis
Yazar:: Maria B. Padua, ve diğerleri
Baskı/Yayın Bilgisi: (2018-05-01)

Targeting HMGCS1 restores chemotherapy sensitivity in acute myeloid leukemia
Yazar:: Cheng Zhou, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

A Luminous Precursor in the Extremely Bright GRB 230307A
Yazar:: S. Dichiara, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study
Yazar:: Humberto Parada, ve diğerleri
Baskı/Yayın Bilgisi: (2017-12-01)

Cellular organization and molecular differentiation model of breast cancer-associated fibroblasts
Yazar:: Susann Busch, ve diğerleri
Baskı/Yayın Bilgisi: (2017-04-01)

Immunohistochemical Evaluation of Basal and Luminal Markers in Bladder Cancer: A Study from a Single Institution
Yazar:: Anh Toan Do, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use
Yazar:: Vipulkumar Dadhania, ve diğerleri
Baskı/Yayın Bilgisi: (2016-10-01)

Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers.
Yazar:: Doris Kim, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

Transcriptome analysis of basal and luminal tumor-initiating cells in ErbB2-driven breast cancer
Yazar:: Nicholas Borcherding, ve diğerleri
Baskı/Yayın Bilgisi: (2015-06-01)

HMGCS2 and AMACR as potential targets linking mitochondrial dysfunction and ulcerative colitis
Yazar:: Rui Zhu, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Liver HMGCS2 is critical in the maintenance of liver lipid homeostasis during fasting
Yazar:: Yunfeng Zhou, ve diğerleri
Baskı/Yayın Bilgisi: (2023-05-01)

Hmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis
Yazar:: Shaza Asif, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

KLF13 suppresses the proliferation and growth of colorectal cancer cells through transcriptionally inhibiting HMGCS1-mediated cholesterol biosynthesis
Yazar:: Weilong Yao, ve diğerleri
Baskı/Yayın Bilgisi: (2020-06-01)

The mevalonate pathway in <it>C. Elegans</it>
Yazar:: Rauthan Manish, ve diğerleri
Baskı/Yayın Bilgisi: (2011-12-01)

Mevalonate Metabolism in Immuno-Oncology
Yazar:: Georg Gruenbacher, ve diğerleri
Baskı/Yayın Bilgisi: (2017-12-01)

Expression of housekeeping genes varies depending on mevalonate pathway inhibition in cancer cells
Yazar:: Nanami Irie, ve diğerleri
Baskı/Yayın Bilgisi: (2023-07-01)

NFYC-37 promotes tumor growth by activating the mevalonate pathway in bladder cancer
Yazar:: Zefu Liu, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer
Yazar:: Natalia Ricco, ve diğerleri
Baskı/Yayın Bilgisi: (2019-09-01)